Allergan PLC (AGN)

240.53
NYSE : Health Care
Prev Close 240.53
Day Low/High 0.00 / 0.00
52 Wk Low/High 184.50 / 277.96
Avg Volume 3.57M
Exchange NYSE
Shares Outstanding 335.58M
Market Cap 80.33B
EPS 38.20
P/E Ratio N/A
Div & Yield 2.80 (1.20%)

Latest News

Short Interest In Allergan Declines 39.3%

Short Interest In Allergan Declines 39.3%

The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 5,524,975 share decrease in total short interest for Allergan PLC , to 8,520,757, a decrease of 39.34% since 02/28/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Has Allergan's Pullback Ended?

Has Allergan's Pullback Ended?

Shares of Allergan are gaining for the third straight session and, at midday, are trading above last week's high.

Dow Drops Triple Digits as Trumpcare Fails, Worries Rise Over President's Agenda

Dow Drops Triple Digits as Trumpcare Fails, Worries Rise Over President's Agenda

Stocks fall on Monday morning as Donald Trump's failure to push through health care reform raises doubts over his ability to enact other promised changes.

Skincare Makers Lead Biotech Movers

Skincare Makers Lead Biotech Movers

Paratek Pharmaceuticals soared while Foamix floundered ahead of market's open.

Twitter, Netflix, MetLife: Doug Kass' Views

Twitter, Netflix, MetLife: Doug Kass' Views

Doug Kass shares his thoughts on Twitter and talks about Sears.

Alphabet, Allergan, Ford: Doug Kass' Views

Alphabet, Allergan, Ford: Doug Kass' Views

Doug Kass shares his thoughts on Alphabet, Allergan and Ford.

Can This Pharma Stock Withstand the 'Trump Effect'?

Can This Pharma Stock Withstand the 'Trump Effect'?

With a 100-plus-year history, generous dividend, and diversified portfolio, could this Big Pharma player be resistant to Trump's drug price twitterstorm?

Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap (Thursday 3/23/17)

Legislative Circus Is Stalling Stocks: Cramer's 'Mad Money' Recap (Thursday 3/23/17)

Brouhaha over GOP-led health-care deal is not really threatening the Republic. But you should have an investment plan in place.

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Cramer: 3 Health Care Bill Scenarios, 3 Game Plans

Get your plan in place, but understand that the Republic is not in jeopardy.

JUVEDERM VOLLUREā„¢ XC Approved By U.S. FDA For Correction Of Facial Wrinkles And Folds In Adults Over The Age Of 21

JUVEDERM VOLLUREā„¢ XC Approved By U.S. FDA For Correction Of Facial Wrinkles And Folds In Adults Over The Age Of 21

First and Only Hyaluronic Acid (HA) Dermal Filler FDA Approved for the Correction of Moderate to Severe Wrinkles and Folds, such as Nasolabial Folds, That Lasts up to 18 Months(1,2*)

Weekly Roundup

Fed's rate hike gives markets a midweek boost. In the portfolio, we trim 1 position and add to 3 others.

When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)

When Very Predictable Is Highly Profitable: Cramer's 'Mad Money' Recap (Wednesday 3/15/17)

Jim Cramer says economic fundamentals remain strong and this market's rallying with relief at Fed's anticipated rate hike.

Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases

Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases

The deal announced Tuesday gives Allergan exclusive access to five Editas programs aimed at serious, inherited eye diseases.

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira

Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.

New Survey Reveals Impact Of Double Chin On Self-Perception And Behavior

New Survey Reveals Impact Of Double Chin On Self-Perception And Behavior

47% OF RESPONDENTS SAID THEY ARE BOTHERED BY THE APPEARANCE OF THE AREA UNDER THEIR CHIN(1)

Award Winning Actor And Hip-Hop Artist Common Joins Allergan's See America(SM) Initiative To Further The Fight Against Preventable Blindness

Award Winning Actor And Hip-Hop Artist Common Joins Allergan's See America(SM) Initiative To Further The Fight Against Preventable Blindness

Common Encourages Americans to Take Action When it Comes to Their Vision Care and Visit their Eye Doctor

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Allergan, Schlumberger, Caterpillar: Doug Kass' Views

Doug Kass shares his thoughts on Allergan, and says that Caterpillar remains purr-fect for shorting.

Google, Apple, Starbucks: Doug Kass' Views

Google, Apple, Starbucks: Doug Kass' Views

Doug Kass shares his thoughts on the state of the market, and notices that the irrational might now be rationalized.

Weekly Roundup

After the jobs report, the markets look ahead to the Fed. In the portfolio, we exit a position while adding to 4 others.

Egalet Makes Friday's Biotech Mailbag

Egalet Makes Friday's Biotech Mailbag

Why the name is sagging, and what it will take to spur the sector higher.

A Lesson on the Importance of Cash

To put it simply, Stanley Black & Decker and Thermo Fisher screwed up.

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

Why Battered Biotech Teva Is a Smart Contrarian Buy Right Now

A firestorm in Washington has created a fire sale for shares of this undervalued stock.

FDA Accepts Supplemental New Drug Application (sNDA) For VRAYLAR (cariprazine)

FDA Accepts Supplemental New Drug Application (sNDA) For VRAYLAR (cariprazine)

- Application Seeks to Expand VRAYLAR Label to Include Phase 3 Clinical Data for the Maintenance Treatment of Schizophrenia-

Logitech: Cramer's Top Takeaways

Logitech: Cramer's Top Takeaways

Logitech CEO Bracken Darrell tells Jim Cramer that the cloud is the new growth platform for Logitech.

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Treehouse Foods, Arconic, Kinder Morgan, Chesapeake Energy: 'Mad Money' Lightning Round

Jim Cramer is bullish on Arconic, Treehouse Foods, Magellan Midstream Partners.

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Trump's Tweet Creates Opportunity in Pharma: Cramer's 'Mad Money' Recap (Tuesday 2/7/17)

Jim Cramer says if Trump really wants to lower drug prices, he should target our trading partners.

Tesla's Cyclical Winter of Discontent: Cramer's 'Off the Charts'

Tesla's Cyclical Winter of Discontent: Cramer's 'Off the Charts'

Tesla's slide doesn't spell doom for other carmakers and it might be a buying opportunity for some investors, says Jim Cramer.